Pancreatic Carcinoma Metastatic
Conditions
Keywords
Metastatic Pancreatic Adenocarcinoma, Elderly, Nab-paclitaxel, Gemcitabine
Brief summary
Cancer incidence is increasing with age and the likelihood of elderly suffering from cancer is 1:3. Although many clinical trials include elderly patients, no results for this subgroup of patients are available. Since there is no specific recommendations for treatment of elderly patients with pancreatic cancer, treatment with gemcitabine alone is the treatment of choice for these patients. Single-agent gemcitabine is the current standard of care, but the addition of cytotoxic and targeted agents to gemcitabine has almost invariably provided no significant survival improvement. Results obtained recently in the MPACT phase III clinical trial in patients with pancreatic cancer treated with nab-paclitaxel combined with gemcitabine have shown improvement in overall survival, but due to in this clinical trial was included patients between 27 and 88 years, it is considered necessary to conduct a specific study for patients over 70 years. The aim of this study is to investigate whether the clinical benefit of nab-paclitaxel associated with gemcitabine can be extended to elderly patients with pancreatic cancer.
Interventions
DRUGNab-paclitaxel 125 mg/m2 weeks 1,2,3/4
Nab-paclitaxel 125 mg/m2 days 1,8 & 15 in a 28 days cycle
DRUGGemcitabine 1000 weeks 1,2,3/4
Gemcitabine 1000 days 1,8 & 15 in a 28 days cycle
Sponsors
Apices Soluciones S.L.
Celgene
Asociación de Oncología Médica del Hospital de Cruces
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically-confirmed pancreatic adenocarcinoma * Stage IV disease (metastatic only) * No prior systemic therapy for their diagnosis (except in adjuvant setting \> six months previously) * ECOG performance status of 0-1 * Age \>=70 years. * Evidence of either or both of the following: * RECIST-defined measurable disease (lesions that can be accurately measured in at least one dimension with the longest diameter \>= 20mm using conventional techniques or \>= 10 mm with spiral CT scan) * An elevated serum CA19-9 at baseline ( \>= 2X ULN) * Female patients must be either surgically sterile or postmenopausal. * Male patients must be surgically sterile or must agree to use a condom during sex with women who may become pregnant while receiving the study drug and for 6 months after receiving the last dose. * Adequate bone marrow function: * ANC \>= 1500/uL * platelet count \>= 100,000/uL * hemoglobin \>= 9.0 g/dL * Adequate hepatic function: * Total bilirubin \<= 1.5 X ULN * AST (SGOT) \<= 2.5 X ULN * ALT (SGPT) \<= 2.5 X ULN * Adequate renal function as determined by either: * Serum creatinine \<= 1.5 X ULN * Calculated or measured creatinine clearance \>= 40 mL/min (for calculated creatinine clearance, Cockroft-Gault equation will be used). * Ability to understand the nature of this study protocol and give written informed consent * Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
Exclusion criteria
* Any prior systemic or investigational therapy for metastatic pancreatic cancer. * Inability to comply with study and/or follow-up procedures. * History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that, in the opinion of the investigator, renders the subject at high risk from treatment complications or might affect the interpretation of the results of the study. * Presence of central nervous system or brain metastases. * Life expectancy \< 12 weeks. * Pregnancy (positive pregnancy test) or lactation. * Prior malignancy except for adequately treated basal cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other form of cancer from which the patient has been disease-free for 5 years. * Clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months. * Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome. * Known, existing uncontrolled coagulopathy. * Pre-existing sensory neuropathy \> grade 1. * Major surgery within 4 weeks of the start of study treatment, without complete recovery. * Concurrent/pre-existing use of anticoagulant treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of treatment through 3-months deterioration free rate | Up to 3 months | The general deterioration of the patient is assessed with the EORTC-QLQ-C30 scale. t will be considered definitive deterioration a decrease of at least 10 points from baseline. We will evaluate the rate of patients free of definitive deterioration at 3 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate safety profile of gemcitabine and nab-paclitaxel, measured by Number of events per patient according to NCI-CTC-AE criteria | Up to 6 months | Number of events per patient according to NCI-CTC-AE criteria |
| Time to tumor progression | Up to 8 months | Time from patient inclusion to disease progression according RECIST criteria |
| Overall survival | Up to 12 months | Time from patient inclusion to death |
| Objective radiographic response (ORR) | Up to 6 months | Response rate will be evaluated according RECIST criteria |
| CA 19.9 biomarker response | Up to 6 months | CA 19.9 biomarker response will be considered a decrease of at least 50% compared to baseline |
Countries
Spain
Outcome results
None listed